

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5271268

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
DERMIRA, INC.	12/03/2018
RECEIVING PARTY DATA	
Name:	ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Street Address:	530 FIFTH AVENUE
Internal Address:	FLOOR 25
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10036
PROPERTY NUMBERS Total: 38	
Property Type	Number
Patent Number:	7504228
Patent Number:	8558008
Patent Number:	9006461
Patent Number:	8859610
Patent Number:	9006462
Patent Number:	9259414
Patent Number:	9610278
Patent Number:	10004717
Application Number:	15996353
Patent Number:	9926270
Application Number:	15895685
Patent Number:	9444056
Patent Number:	10092736
Patent Number:	9975867
PCT Number:	US2017044988
Patent Number:	9487497
Patent Number:	9745277
PCT Number:	US2017044020
Application Number:	15660520

PATENT

Property Type	Number
Patent Number:	5962505
Patent Number:	6395757
Patent Number:	6433003
Patent Number:	8618160
Patent Number:	9744105
Patent Number:	10052267
Application Number:	15994232
Patent Number:	8067199
Patent Number:	8088618
Patent Number:	8734801
Patent Number:	9067994
Patent Number:	9605065
PCT Number:	US2012062572
Patent Number:	10000562
Application Number:	16002932
PCT Number:	US2014055387
Patent Number:	9920120
PCT Number:	US2017052891
Application Number:	90006468

CORRESPONDENCE DATA

Fax Number: (704)378-2057

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7043312359

Email: iplaw@mvalaw.com, cindigraser@mvalaw.com

Correspondent Name: MOORE & VAN ALLEN PLLC

Address Line 1: 3015 CARRINGTON MILL BOULEVARD, STE 400

Address Line 2: POST OFFICE BOX 13706

Address Line 4: RESEARCH TRIANGLE PA, NORTH CAROLINA 27709

ATTORNEY DOCKET NUMBER:	036251.000054
NAME OF SUBMITTER:	JAMES VAN CLEAVE GAMBRELL
SIGNATURE:	/James Van Cleave Gambrell/
DATE SIGNED:	12/07/2018

Total Attachments: 6

source=036251-54-patent security interest#page1.tif

source=036251-54-patent security interest#page2.tif

source=036251-54-patent security interest#page3.tif

source=036251-54-patent security interest#page4.tif

source=036251-54-patent security interest#page5.tif

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
PATENTS

United States Patent and Trademark Office

Ladies and Gentlemen:

Please be advised that pursuant to the Security Agreement dated as of December 3, 2018 (as the same may be amended, modified, restated or supplemented from time to time, the “Security Agreement”) by and among the Grantors party thereto (each a “Grantor” and collectively, the “Grantors”) and Athyrium Opportunities III Acquisition LP, as Administrative Agent (the “Administrative Agent”) for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, any and all of its patents, patent licenses and patent applications, including those patents, exclusive patent licenses and patent applications that constitute Material Intellectual Property set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the patents, patent licenses and patent applications of the undersigned Grantor, including those set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement, (ii) is not to be construed as an assignment of any patent, patent license or patent application.

[Signature pages follow]

Very truly yours,

DERMIRA, INC.,
a Delaware corporation

By: 

Name: Andrew L. Guggenhime
Title: Chief Financial Officer

IP NOTICE
DERMIRA, INC.

PATENT

REEL: 047701 FRAME: 0469


Acknowledged and Accepted:

ADMINISTRATIVE AGENT:

ATHYRIUM OPPORTUNITIES III ACQUISITION LP,
a Delaware limited partnership

By: ATHYRIUM OPPORTUNITIES
ASSOCIATES III LP, its General Partner

By: ATHYRIUM OPPORTUNITIES
ASSOCIATES III GP LLC, its General Partner

By: 
Name: Andrew C. Hyman
Title: Authorized Signatory

IP NOTICE
DERMIRA, INC.

PATENT
REEL: 047701 FRAME: 0470

SCHEDULE 1

Patents Assigned to Dermira, Inc.

Country	Application No.	Filing Date	Title	Patent Number
US	10/163,599	6/5/2002	Integrin Linked Kinase Modulation of Macrophase Activation	7504228
US	13/781,390	2/28/2013	Crystalline Glycopyrrolate Tosylate	8558008
US	14/024,480	9/11/2013	Crystalline Glycopyrrolate Tosylate	9006461
US	14/024,484	9/11/2013	Crystalline Glycopyrrolate Tosylate	8859610
US	14/473,537	8/29/2014	Glycopyrrolate Salts	9006462
US	14/643,553	3/10/2015	Glycopyrrolate Salts	9259414
US	14/989,995	1/7/2016	Glycopyrrolate Salts	9610278
US	15/438,636	2/21/2017	Glycopyrrolate Salts	10004717
US	15/996,353	6/1/2018	Glycopyrrolate Salts	
US	14/830,638	8/19/2015	Process for Production of Glycopyrrolate Tosylate	9,926,270
US	15/895,685	2/13/2018	Process for Production of Glycopyrrolate Tosylate	
US	14/869,799	9/29/2015	Device and Method for Dispensing a Drug	9,444,056
US	15/146,627	5/4/2016	Device and Method for Dispensing a Drug	10092736
WO	PCT/US2017/044988	8/1/2017	Process for Making, and Methods of Using, Glycopyrrolate Compounds	
US	US15015569	2/4/2016	Synthetic process for preparing 2-furoic acid derivatives	US9975867B2
US	US15015828	2/4/2016	Synthetic process for preparing 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxyfuran-2-carboxylate	US9487497B2
US	US15284319	10/3/2016	Synthetic process for preparing 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxyfuran-2-carboxylate	US9745277B2

Country	Application No.	Filing Date	Title	Patent Number
US	10/163,599	6/5/2002	Integrin Linked Kinase Modulation of Macrophase Activation	7504228
US	US15660520	7/26/2017	Dermatological Formulations of 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE	
WO	PCT/US2017/044020	7/26/2017	Dermatological Formulations of 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE	N/A

Patents Licensed to Dermira, Inc.

Administrative Agents has received a security in Grantor's rights as licensee to the following patents:

Country	Application No.	Filing Date	Title	Patent Number	Licensor
US	09/184,512	11/2/1998	Method for Treating Hot Flashes in Humans	5962505	ROSE U, LLC
US	09/317,670	5/24/1999	Method for Treating Hot Flashes in Humans	6395757	ROSE U, LLC
US	09/360,074	7/23/1999	Method for Treating Hot Flashes in Humans		ROSE U, LLC
US	09/552,011	4/19/2000	Method for Treating Hyperhidrosis in Mammals	6433003	ROSE U, LLC
US	90/006,468	11/29/2002	Method for treating hyperhidrosis in mammals	6433003	ROSE U, LLC
US	12/738,168	10/17/2008	Topical Glycopyrrolate Formulations	8618160	ROSE U, LLC
US	14/084,010	11/19/2013	Topical Glycopyrrolate Formulations	9744105	ROSE U, LLC
US	15/662,166	7/27/2017	Topical Glycopyrrolate Formulations	10052267	ROSE U, LLC
US	15/994,232	5/31/2018	Topical Glycopyrrolate Formulations		ROSE U, LLC
WO	PCT/US2004/043501	12/23/2004	NOVEL ANTI-IL 13 ANTIBODIES AND USES THEREOF		Roche
US	US10583927	12/23/2004	Anti-IL13 antibodies and uses thereof	US8067199B2	Roche
US	US12240604	9/29/2008	Anti-IL 13 antibodies and uses thereof	US8088618B2	Roche

Country	Application No.	Filing Date	Title	Patent Number	Licensor
US	US13275684	10/18/2011	Anti-IL13 antibodies and uses thereof	US8734801B2	Roche
US	US13308186	11/30/2011	Anti-IL13 antibodies and uses thereof	US9067994B2	Roche
US	US13971394	8/20/2013	Anti-IL13 antibodies and uses thereof	US9605065B2	Roche
WO	PCT/US2012/062572	10/30/2012	ANTIBODY FORMULATIONS		Roche
US	US14259882	4/23/2014	Antibody formulations	US10000562B2	Roche
US	US16/002,932	6/7/2018	Antibody Formulations		Roche
WO	PCT/US2014/055387	9/12/2014	METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES		Roche
US	US15065693	3/9/2016	Methods and compositions comprising purified recombinant polypeptides	US9920120B2	Roche
WO	PCT/US2017/052891	9/22/2017	USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS		Roche